Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846480 | PMC |
| http://dx.doi.org/10.1097/CM9.0000000000001184 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Copper metabolism-related lncRNAs predict prognosis and immune landscape in liver cancer patients.
Transl Cancer Res
November 2024
Department of Gastroenterology, the Affiliated Hospital of Southwest Medical University, Luzhou, China.
Background: Characterized by its high mortality and easy recurrence, hepatocellular carcinoma (HCC) poses significant clinical challenges. The association between copper metabolism and development of cancer has been identified. However, the underlying mechanisms of copper metabolism-related long non-coding RNAs (CMRLs) in HCC remain elusive.
View Article and Find Full Text PDFUtilization of EGFR, ALK, and BRAF Inhibitors in the Treatment of Lung Cancer in Germany.
Cancer Rep (Hoboken)
December 2024
Department of Clinical Epidemiology, Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany.
Background: There is a lack of real-world data on the use of targeted cancer drugs requiring molecular tumor diagnostics in the treatment of lung cancer in Germany.
Aims: We aimed to characterize the use of such drugs in lung cancer patients based on longitudinal analyses.
Methods And Results: Using the GePaRD database (claims data from ~20% of the German population) we identified lung cancer patients diagnosed in 2016 based on a previously developed algorithm and followed them until death, end of continuous insurance, or end of 2019.
Real-World Data Presenting the Descriptive Analysis of the Use of Tyrosine Kinase Inhibitors (TKIs) Among Metastatic Non-Small-Cell Lung Cancer (mNSCLC) Patients in Qatar: A Nationwide Retrospective Cohort Study.
Clin Med Insights Oncol
October 2024
Department of Pharmacy, The National Center of Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
Background: There has been significant improvement in treating metastatic non-small-cell lung cancer (mNSCLC) over the past 2 decades. The aim of this study is to describe the use of tyrosine kinase inhibitors (TKIs) in Qatar. This study focuses on the objective response rate (ORR) and reported adverse drug events (ADEs) of TKIs used for the management of patients with mNSCLC.
View Article and Find Full Text PDFCase report: Durable response of ensartinib targeting EML4-ALK fusion in osimertinib-resistant non-small cell lung cancer.
Front Pharmacol
July 2024
Department of Pulmonary Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Background: Despite significant benefits from targeted therapy in patients with driver mutations, inevitable drug resistance usually occurred in non-small cell lung cancer, highlighting the necessity for sequential treatments to prolong overall survival. Unfortunately, durable drug response has not been reported in posterior-line therapy of cases with acquired fusion after resistance to osimertinib, urging the need of referable decision-making in clinical management.
Case Presentation: We present a case of a 71-year-old Chinese female, never smoker, diagnosed with invasive adenocarcinoma in the left inferior lobe of her lung, with metastases in regional lymph nodes.
Prolonged Response to Afatinib and Crizotinib in a Rare Case of -, -, - and -Alterated Lung Adenocarcinoma.
Int J Mol Sci
May 2024
Department of Medical Oncology and Haematology, Cantonal Hospital St. Gallen, Rorschacher Strasse 95, 9007 St. Gallen, Switzerland.
Article Synopsis
- A 70-year-old woman with metastatic non-small cell lung cancer (NSCLC) initially responded to erlotinib, but after progression, she was treated with platinum/pemetrexed and had a favorable outcome for over two years.
- After further testing of her cancer revealed new mutations alongside an existing one, she transitioned to crizotinib, achieving a 17-month response before it was combined with afatinib, leading to another two-year improvement.
- This case highlights the importance of ongoing molecular testing in metastatic NSCLC, as it can uncover new mutations that enable more effective treatment options and enhance patient survival.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!